These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 14962263

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
    Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM.
    Cancer; 2006 May 01; 106(9):1974-84. PubMed ID: 16583431
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide.
    Strupp C, Fenk R, Kündgen A, Gattermann N, Haas R, Germing U.
    Leuk Res; 2005 Aug 01; 29(8):967-9. PubMed ID: 15978949
    [Abstract] [Full Text] [Related]

  • 5. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
    Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S, Demory JL, Ilariucci F, Volpe A, Bordessoule D, Grossi A, Le Bousse-Kerdiles MC, Caenazzo A, Pecci A, Falcone A, Broccia G, Bendotti C, Bauduer F, Buccisano F, Dupriez B.
    J Clin Oncol; 2004 Feb 01; 22(3):424-31. PubMed ID: 14752066
    [Abstract] [Full Text] [Related]

  • 6. Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new.
    Tefferi A.
    Semin Hematol; 2003 Jan 01; 40(1 Suppl 1):18-21. PubMed ID: 12682877
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
    McMeekin DS, Sill MW, Darcy KM, Stearns-Kurosawa DJ, Webster K, Waggoner S, Benbrook D.
    Gynecol Oncol; 2007 Sep 01; 106(3):596-603. PubMed ID: 17597196
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.
    Mesa RA.
    Curr Hematol Rep; 2003 May 01; 2(3):264-70. PubMed ID: 12901349
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.
    Thapaliya P, Tefferi A, Pardanani A, Steensma DP, Camoriano J, Wu W, Geyer S, Mesa RA.
    Am J Hematol; 2011 Jan 01; 86(1):96-8. PubMed ID: 21132732
    [Abstract] [Full Text] [Related]

  • 14. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
    Cibeira MT, Rosiñol L, Ramiro L, Esteve J, Torrebadell M, Bladé J.
    Eur J Haematol; 2006 Dec 01; 77(6):486-92. PubMed ID: 16978238
    [Abstract] [Full Text] [Related]

  • 15. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
    Pinter M, Wichlas M, Schmid K, Plank C, Müller C, Wrba F, Peck-Radosavljevic M.
    Eur J Gastroenterol Hepatol; 2008 Oct 01; 20(10):1012-9. PubMed ID: 18787470
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.
    Abgrall JF, Guibaud I, Bastie JN, Flesch M, Rossi JF, Lacotte-Thierry L, Boyer F, Casassus P, Slama B, Berthou C, Rodon P, Leporrier M, Villemagne B, Himberlin C, Ghomari K, Larosa F, Rollot F, Dugay J, Allard C, Maigre M, Isnard F, Zerbib R, Cauvin JM, Groupe Ouest-Est Leucémies et Maladies du Sang (GOELAMS).
    Haematologica; 2006 Aug 01; 91(8):1027-32. PubMed ID: 16885042
    [Abstract] [Full Text] [Related]

  • 19. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
    Palumbo A, Avonto I, Bruno B, Ambrosini MT, Bringhen S, Cavallo F, Falco P, Boccadoro M.
    Eur J Haematol; 2006 Apr 01; 76(4):273-7. PubMed ID: 16519697
    [Abstract] [Full Text] [Related]

  • 20. Low-dose thalidomide in myelofibrosis.
    Weinkove R, Reilly JT, McMullin MF, Curtin NJ, Radia D, Harrison CN.
    Haematologica; 2008 Jul 01; 93(7):1100-1. PubMed ID: 18508796
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.